A US biotech startup has relocated its corporate headquarters, lab, and manufacturing capabilities to a Netrality data center in Pennsylvania.
Biomeme, a manufacturer of portable, real-time polymerase chain reaction (PCR) testing solutions has selected Netrality’s 401 North Broad Street in Philadelphia, Pennsylvania for its new corporate headquarters.
The 44,000 square foot space will house Biomeme’s laboratory, testing, manufacturing, fulfillment and office operations.
“Netrality’s 401 North Broad is the ideal home for our new headquarters. We’re excited to expand our research and development, manufacturing, and operations within Center City, ” said Max Perelman, co-founder and business lead of Biomeme.
For more breaking data center news, features, and opinions, be sure to subscribe to DCD's newsletter
Data center makes a good lab and manufacturing facility
Biomeme was previously at 10th and Chestnut in the city but has grown from 35 employees to over 280 in the last year, with 120 in and around Philadelphia. It and has been working with Strada Architecture LLC to build out the new space, which it plans to move into by the end of the year. According to Netrality’s site, the 11-story North Broad Street site totals 1,400,794 sq ft and has a total capacity of 40MW.
“Netrality is proud to bring Biomeme into our robust ecosystem of life science, digital health, and tech-enabled companies that are uncovering cutting-edge solutions,” said Gerald M. Marshall, CEO of Netrality Data Centers. “As the epicenter of connectivity in Philadelphia, Netrality provides the foundational elements for life sciences and biotech companies like Biomeme to access mission-critical infrastructure and continuous uptime as they continue advancing healthcare technology, including the fight against Covid-19.”
Biomeme says the new facility will expand its production capacity for mobile RT-PCR devices, lyophilized and shelf-stable real-time PCR tests -- including their FDA emergency use-authorized Covid-19 test - and sample preparation products.
“401 North Broad meets or exceeds all of the key requirements for our lab and manufacturing use, including heavy floor loading, wide column spacing, high ceilings, redundant electric utility feeds, ample available backup power, excellent mechanical systems including supply and exhaust air ventilation, secure loading docks and robust network connectivity," added Karen Griffith Gryga, Operations Lead of Biomeme.
Amerimar Enterprises and Abrams Capital acquired the carrier hotel at 401 North Broad in 2014 and launched Netrality Properties the following year. Macquarie Infrastructure Partners acquired the company in 2019.
